OTC: BSEM

BioStem Technologies, Inc.

CIK 0001658678 · SIC 2836 · Biological Products

Micro Revenue $47M Assets $49M as of Oct 18, 2026

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.

424B3 Filed Oct 13, 2026

Summary not yet generated.

S-1 Filed Oct 2, 2026

Summary not yet generated.

Partner

Trade BSEM commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed Sep 30, 2026 · Period ending Sep 29, 2026

Summary not yet generated.

424B3 Filed Sep 29, 2026

Summary not yet generated.

8-K Filed Sep 18, 2026 · Period ending Sep 18, 2026

Summary not yet generated.

S-1 Filed Sep 18, 2026

Summary not yet generated.

424B3 Filed Aug 14, 2026

BioStem Technologies files prospectus supplement for sale of up to 3.57 million shares; stock last closed at $3.10

2 material changes detected. Sign up free to read the summary.

View report
424B3 Filed Aug 13, 2026

Summary not yet generated.

10-Q Filed Aug 12, 2026 · Period ending Jun 30, 2026

Summary not yet generated.

8-K Filed Aug 12, 2026 · Period ending Aug 12, 2026

Summary not yet generated.

S-1/A Filed Aug 7, 2026 Red flag

BioStem Technologies uplists to Nasdaq; shares now trade at $4.09

3 material changes detected. Sign up free to read the summary.

View report
8-K Filed Aug 7, 2026 · Period ending Aug 6, 2026

Summary not yet generated.

S-1 Filed Jul 29, 2026

Summary not yet generated.

Latest financial statements

From 10-Q filed Aug 12, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Condensed Consolidated Statements of Operations (Unaudited)

Description Three months ended June 30, 2026 Three months ended June 30, 2025 Six months ended June 30, 2026 Six months ended June 30, 2025
Revenue, net 7,899,249 10,963,174 14,034,779 26,930,195
Cost of goods sold 3,058,588 685,177 5,434,627 1,538,615
Gross profit 4,840,661 10,277,997 8,600,152 25,391,580
Sales and marketing expenses 5,321,885 1,275,150 9,067,472 2,398,528
General and administrative expenses 6,496,530 6,871,997 13,717,319 13,868,762
Research and development expenses 733,616 1,957,352 1,870,845 3,647,506
Depreciation and amortization expense 689,317 60,739 1,229,754 114,700
Total operating expenses 13,241,348 10,165,238 25,885,390 20,029,496
(Loss) income from operations (8,400,687) 112,759 (17,285,238) 5,362,084
Other (expense) income:
Interest income, net 23,362 64,785 87,037 93,332
Other (expense) income (594,035) 409 (592,864) 3,070
Other (expense) income, net (570,673) 65,194 (505,827) 96,402
Total (loss) income from operations before income taxes (8,971,360) 177,953 (17,791,065) 5,458,486
Income tax expense - (167,340) - (1,539,751)
Net (loss) income (8,971,360) 10,613 (17,791,065) 3,918,735
Basic net (loss) income per share attributable to common stockholders (0.52) 0.00 (1.04) 0.23
Diluted net (loss) income per share attributable to common stockholders (0.52) 0.00 (1.04) 0.17
Basic weighted average common shares outstanding 17,327,652 16,708,776 17,090,140 16,689,537
Diluted weighted average common shares outstanding 17,327,652 23,419,726 17,090,140 23,508,268

Condensed Consolidated Balance Sheets

Description As of June 30, 2026 (Unaudited) As of December 31, 2025
ASSETS
Current Assets
Cash and cash equivalents 6,962,492 29,549,018
Accounts receivable, net of allowance of $9,023,768 as of June 30, 2026 and December 31, 2025, respectively 6,621,357 9,874,468
Inventory 4,711,775 2,877,160
Prepaid expenses and other assets 2,485,430 2,102,803
Total current assets 20,781,054 44,403,449
Long-Term Assets
Property and equipment, net 4,419,563 3,970,513
Construction-in-process 505,307 961,032
Right-of-use asset, net 220,551 327,267
Intangible assets, net 21,359,186 119,765
Goodwill 1,532,635 244,635
Total assets 48,818,296 50,026,661
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued expenses 9,457,957 4,441,419
License fees payable 434,775 729,975
Income tax payable - 31,512
Accrued interest 11,333 2,227,500
Operating lease liabilities 222,471 225,768
Notes payable 1,000,000 3,000,000
Contingent consideration payable 10,000,000 -
Other current liabilities 75,808 127,406
Total current liabilities 21,202,344 10,783,580
Long-Term Liabilities
Operating lease liabilities, less current portion 1,355 105,262
Total long-term liabilities 1,355 105,262
Total liabilities 21,203,699 10,888,842
Commitments and contingencies (Note 13)
Stockholders' Equity
Series A-1 convertible preferred stock, $0.001 par value; authorized 300 shares; issued and outstanding 300 shares as of June 30, 2026 and December 31, 2025. - -
Series B-1 convertible preferred stock, $0.001 par value; authorized 500,000 shares; issued and outstanding 5 shares as of June 30, 2026 and December 31, 2025. - -
Common stock, $0.001 par value; authorized 975,000,000 shares; issued and outstanding 17,839,467 and 16,825,716 shares as of June 30, 2026 and December 31, 2025, respectively. 17,841 16,827
Additional paid-in capital 66,605,483 60,338,654
Treasury stock, 18,000 shares at cost (43,346) (43,346)
Accumulated deficit (38,965,381) (21,174,316)
Total stockholders' equity 27,614,597 39,137,819
Total liabilities and stockholders' equity 48,818,296 50,026,661

Condensed Consolidated Statements of Cash Flows (Unaudited)

Description Six months ended June 30 2026 Six months ended June 30 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income (17,791,065) 3,918,735
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation expense 64,600 52,967
Amortization expense 1,165,154 61,734
Amortization of debt discount - 63,607
Amortization of right-of-use asset 106,716 53,559
Stock-based compensation expense 3,914,096 4,872,564
Fair value adjustment to contingent consideration 1,412,000 -
Gain on extinguishment of debt (815,250) -
Deferred tax benefit - (527,450)
Changes in operating assets and liabilities:
Accounts receivable 3,253,111 8,065,416
Inventory (1,834,615) (636,397)
Prepaid expenses and other assets (364,256) (856,192)
Accounts payable and accrued expenses 4,911,963 (279,938)
License fees payable (295,200) (1,916,925)
Income tax payable (31,512) (3,498,045)
Accrued interest 99,083 133,403
Other current and long-term liabilities (158,802) (10,697)
Net cash (used in) provided by operating activities (6,363,977) 9,496,341
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment and construction-in- process (57,925) (497,150)
Cash paid in business combination (15,018,371) -
Net cash used in investing activities (15,076,296) (497,150)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments on notes payable (3,500,000) (1,021,351)
Proceeds from issuance of common stock 2,500,000 -
Cash paid for costs related to the issuance of common stock (146,253) -
Issuance of common stock for warrant exercise - 33,334
Net cash used in financing activities (1,146,253) (988,017)
Cash and cash equivalents:
Net change during the period (22,586,526) 8,011,174
Balance, beginning of period 29,549,018 22,832,706
Balance, end of period 6,962,492 30,843,880
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest 2,316,475 12,717
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Construction-in-process transferred to property and equipment 513,651 21,184
Initial ROU asset and operating lease liability - 214,220
Non-cash contingent consideration payable 8,588,000 -
Development of internal-use software in accounts payable 104,575 -
Promissory note in conjunction with debt extinguishment (Note 10) 1,000,000 -

Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗

View all filings for BSEM on SEC EDGAR